Mabwell Adalimumab Biosimilar Wins Marketing Approval in Indonesia
Mabwell’s adalimumab biosimilar 9MW0113, co-developed with Junshi Biosciences, has received marketing approval from Indonesia’s BPOM, becoming the first China-developed adalimumab biosimilar to secure such approval, as the company advances global expansion with partnerships in over 10 countries.
JUNMAIKANG | 01/01/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy